• For full details of graphics available/in preparation, see Menu -> Planners
 عقار ويغوفي لإنقاص الوزن  infographic
Graphic shows timeline of Novo Nordisk’s rise to Europe’s most valuable company.


عقار ويغوفي لإنقاص الوزن

By Duncan Mil

September 6, 2023 - عقار ويغوفي الرائج لإنقاص الوزن هو الاسم التجاري لعقار سيماغلوتايد، الذي يحاكي عمل الهرمون الذي يُشعر متعاطيه بالشبع، مما يؤدي إلى تناول كميات غذاء أقل.

Shares of the Danish drugmaker have soared 40% this year, boosted by skyrocketing demand for its weight-loss drugs Ozempic and Wegovy.

At the close of trading Monday, Novo Nordisk had a market capitalization of 2.96 trillion Danish krone ($428 billion).

Ozempic and Wegovy are drugs developed to treat type 2 diabetes that contain the same active ingredient -- semaglutide, a GLP-1 (glucagon-like peptide 1) -- which clinical trials have shown can help people lose 15% of their body weight after less than 16 months.

On Monday, Novo Nordisk also announced that Wegovy would now be available in the UK “through a controlled and limited launch.”

“This new generation of medicines [has] the potential to be a game-changer,” UK Health and Social Care Minister Steve Barclay posted on social media site X.

Used for long-term weight management, Wegovy’s high cost -- about $1,350 per month in the U.S. -- can make it unaffordable for many patients unless their insurance covers it.

Novo Nordisk has made almost 49 billion Danish krone ($7 billion) in profit over the first six months of this year, up 30% from the same period in 2022.

PUBLISHED: 06/09/2023; STORY: Graphic News; PICTURES: Getty Images